Jung-Mao Hsu

China Medical University — Taiwan

Biochemistry, Genetics and Molecular Biology · Life Sciences

44h-index13.5kcitations143works32.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Epigenetics and DNA Methylation(20), Cancer-related gene regulation(19), PARP inhibition in cancer therapy(18), Cancer Immunotherapy and Biomarkers(16), Peptidase Inhibition and Analysis(16)

Publications143 total

Toward personalized classification and treatment in depression: A narrative review of digital phenotyping and artificial intelligence
Psychiatry and Clinical Neurosciences·2026Open Access
MTAP deficiency confers resistance to cytosolic nucleic acid sensing and STING agonists
Science·2025· 2 cited
Advances and prospects of biomarkers for immune checkpoint inhibitors
Cell Reports Medicine·2024· 94 citedOpen Access
Gasdermins and cancers
Seminars in Immunology·2023· 13 cited
Supplementary Figure Legend from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
2023Open Access
Supplementary Figure 3 from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
2023Open Access
Supplementary Figure 3 from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
2023Open Access
Data from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
2023Open Access
Supplementary Figure 1 from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
2023Open Access
Supplementary Figure 4 from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
2023Open Access
Supplementary Figure Legend from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
2023Open Access
Supplementary Figure 1 from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
2023Open Access
Supplementary Table 1 from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
2023Open Access
Supplementary Figure 4 from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
2023Open Access
Supplementary Figure 2 from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
2023Open Access
Supplementary Figure 2 from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
2023Open Access
Data from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
2023Open Access
Supplementary Table 1 from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
2023Open Access
Data from Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation
2023Open Access
Supplementary Movie S4 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Mien‐Chie Hung(40), Weiya Xia(20), Jennifer L. Hsu(16), Chia‐Wei Li(14), Li-Chuan Chan(14), Hirohito Yamaguchi(14), Yongkun Wei(13), Gabriel N. Hortobágyi(10), Chao‐Kai Chou(10), Dung‐Fang Lee(9), Linlin Sun(9), Seung-Oe Lim(8), Heng‐Huan Lee(8), Jong‐Ho Cha(8), Wei-Chao Chang(8), Sam S. Chang(7), Qingqing Ding(7), Dihua Yu(7), Chun‐Te Chen(7), Long‐Yuan Li(7)